New data shows widespread undetected metabolic risk – even among “healthy” individuals – as Noom enables members to test, ...

For the past three years, nearly every breakthrough in obesity medicine has traced back to a single class of drugs: GLP-1 receptor agonists like semaglutide and tirzepatide. Now, a phase 2 clinical ...

Biochemist Svetlana Mojsov, PhD, has been awarded the Frontiers of Knowledge Award in Biology and Biomedicine, presented by Spain’s BBVA Foundation, for her collaborative research with Daniel Drucker, ...

Obesity shaped Anna Olson's earliest notions of herself, when she saw a photo and thought, "Oh, I look different than the other kids." Olson's obesity began in toddlerhood, ran in her family, and left ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Balding might make you blue — but this news won’t.  A recent study suggests that a controversial liquid popular in biohacking ...

Emerging research shows there are ‘super-responders’ to GLP-1 drugs, and others who don’t respond at all.

Treatment for diabetes and obesity is rapidly evolving, with multi-targeted approaches taking shape. Medications like semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, have set high ...

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Hims & Hers Health ...